17. The method as claimed in claim 16, wherein the administration of formulation by inhalation is done by nebulization in which the drug (compound of formula I) is entrapped in microparticles.

18. The method as claimed in claim 17, wherein the retention of the entrapped compound of formula I range from 30 % to 70 %.

19. The method as claimed in claim 16, wherein the drug (compound of formula I), contained in the formulation administered by inhalation is retained in the lungs over a period of 24 hours.

20. The method as claimed in claim 16, wherein the dosage for inhalation ranges between 0.05 and 10 mg/kg body weight/day.

21. The method as claimed in claim 13, wherein said method is non-invasive.

22. Use of the microparticle formulation comprising compound of formula I and a biodegradable lipid for drug delivery wherein the ratio of drug (compound of formula I) to lipid is 1:15 to 1:25 for the treatment of pulmonary tuberculosis, multi drug resistant tuberculosis, methicillin resistant *Staphylococcus aureus* pneumonias or methicillin sensitive *Staphylococcus aureus* pneumonias.

23. Use of the microparticle formulation comprising compound of formula I and a biodegradable lipid for drug delivery wherein the ratio of drug (compound of formula I) to lipid is 1:15 to 1:25 for the manufacture of a medicament for the treatment of pulmonary tuberculosis, multi drug resistant tuberculosis, methicillin resistant *Staphylococcus aureus* pneumonias and methicillin sensitive *Staphylococcus aureus* pneumonias.

24. A microparticle formulation comprising compound of formula I and a biodegradable lipid for drug delivery wherein the ratio of drug (compound of formula I) to lipid is 1:15 to 1:25 for treatment of pulmonary tuberculosis, multi drug resistant tuberculosis, methicillin resistant *Staphylococcus aureus* pneumonias or methicillin sensitive *Staphylococcus aureus* pneumonias.

Dated this 16th day of February 2013.

Ganguli

DR. SANCHITA GANGULI
of S. MAJUMDAR & CO.
Applicants' Agent